董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Russell Greig | 男 | Chairman | 73 | 15.66万美元 | 未持股 | 2025-10-16 |
| Jesse Goodman | 男 | Director | 73 | 5.35万美元 | 未持股 | 2025-10-16 |
| Jonathan Solomon | 男 | Chief Executive Officer and Director | 48 | 107.86万美元 | 未持股 | 2025-10-16 |
| Alan Moses | 男 | Director | 77 | 7.50万美元 | 未持股 | 2025-10-16 |
| Susan Blum | 女 | Director | 53 | 5.76万美元 | 未持股 | 2025-10-16 |
| Jesse Goodman | 男 | Director | 73 | 未披露 | 未持股 | 2025-10-16 |
| Gregory Merril | 男 | Director | 59 | 5.35万美元 | 未持股 | 2025-10-16 |
| Edward Williams | 男 | Director | 69 | 6.08万美元 | 未持股 | 2025-10-16 |
| Jonathan Leff | 男 | Director | 57 | 5.43万美元 | 未持股 | 2025-10-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Solomon | 男 | Chief Executive Officer and Director | 48 | 107.86万美元 | 未持股 | 2025-10-16 |
| Merav Bassan | 女 | Chief Development Officer | 59 | 53.30万美元 | 未持股 | 2025-10-16 |
| Marina Wolfson | 女 | Chief Financial Officer | 41 | 35.16万美元 | 未持股 | 2025-10-16 |
董事简历
中英对照 | 中文 | 英文- Russell Greig
-
Russell Greig，在GlaxoSmithKline任职30年，最近担任SR One（GlaxoSmithKline公司创业集团）的总裁。在加入SR One之前，2003年至2008年，他是GlaxoSmithKline's Pharmaceuticals International的总裁，也是the GlaxoSmithKline企业执行团队的成员。目前，他是荷兰AM Pharma和Mint Solutions、挪威Bionor、西班牙Sanifit的董事长。他也是比利时Ablynx和法国Onxeo Pharma previously BioAlliance Pharma的董事，也是Kurma Life Sciences （法国巴黎）的创业合伙人。他曾担任瑞典Isconova（被美国Novavax收购）， 法国Novagali（被日本Santen收购）， 英国Syntaxin（被法国Ipsen收购）的董事长，以及西班牙Oryzon的董事。
Russell Greig,has more than 44 years' experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline ("GSK"), where he held a number of positions including GSK's President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr. Greig was also President of SR One, GSK's corporate venture group. He is currently Chairman of Nucleome Therapeutics Limited (Oxford, UK). In addition, Dr. Greig previously served on the boards of Sanifit (Spain) acquired by Vifor Pharma AG (SWX: VIFN), Tigenix N.V. (acquired by Takeda Pharmaceutical Company Limited), Ablynx N.V. (acquired by Sanofi, France), Chairman of MedEye NV (formerly - Mint Solutions, The Netherlands), eTheRNA immunotherapies NV (Belgium) and Merus N.V. (Nasdaq: MRUS). He was previously Chairman of Cardior Pharmaceuticals GmbH (Germany) (sold to Novo Nordisk A/S for over $1 billion), Syntaxin Ltd (UK) (sold to Ipsen), Novagali Pharma S.A. (France) (acquired by Santen Pharmaceutical Co., Ltd.), and Isconova AB (Sweden) (acquired by Novavax, Inc. (Nasdaq: NVAX)). He served as acting Chief Executive Officer at Genocea Biosciences (Nasdaq: GNCA) and Isconova AB for an interim period. He was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland. - Russell Greig，在GlaxoSmithKline任职30年，最近担任SR One（GlaxoSmithKline公司创业集团）的总裁。在加入SR One之前，2003年至2008年，他是GlaxoSmithKline's Pharmaceuticals International的总裁，也是the GlaxoSmithKline企业执行团队的成员。目前，他是荷兰AM Pharma和Mint Solutions、挪威Bionor、西班牙Sanifit的董事长。他也是比利时Ablynx和法国Onxeo Pharma previously BioAlliance Pharma的董事，也是Kurma Life Sciences （法国巴黎）的创业合伙人。他曾担任瑞典Isconova（被美国Novavax收购）， 法国Novagali（被日本Santen收购）， 英国Syntaxin（被法国Ipsen收购）的董事长，以及西班牙Oryzon的董事。
- Russell Greig,has more than 44 years' experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline ("GSK"), where he held a number of positions including GSK's President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr. Greig was also President of SR One, GSK's corporate venture group. He is currently Chairman of Nucleome Therapeutics Limited (Oxford, UK). In addition, Dr. Greig previously served on the boards of Sanifit (Spain) acquired by Vifor Pharma AG (SWX: VIFN), Tigenix N.V. (acquired by Takeda Pharmaceutical Company Limited), Ablynx N.V. (acquired by Sanofi, France), Chairman of MedEye NV (formerly - Mint Solutions, The Netherlands), eTheRNA immunotherapies NV (Belgium) and Merus N.V. (Nasdaq: MRUS). He was previously Chairman of Cardior Pharmaceuticals GmbH (Germany) (sold to Novo Nordisk A/S for over $1 billion), Syntaxin Ltd (UK) (sold to Ipsen), Novagali Pharma S.A. (France) (acquired by Santen Pharmaceutical Co., Ltd.), and Isconova AB (Sweden) (acquired by Novavax, Inc. (Nasdaq: NVAX)). He served as acting Chief Executive Officer at Genocea Biosciences (Nasdaq: GNCA) and Isconova AB for an interim period. He was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.
- Jesse Goodman
-
Jesse Goodman， 2014年3月以来，他一直担任Georgetown大学医疗产品准入、安全和管理中心主任，以及医学教授和传染病主治医师。2016年至2025年，他担任跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会成员，并担任董事会科学委员会主席，直到2023年初。自2018年以来，他担任Intellia Therapeutics， Inc.（上市生物技术公司）的董事会成员，现担任其科学和技术委员会主席。在合并协议之前，他曾担任APT董事会成员。他还曾担任美国药典公约公司（United States Pharmacopeia Convention, Inc.）董事会主席（2015年至2020年）和成员（2015年至2025年）。从2009年到2014年2月，他担任FDA的首席科学家。从2009年到2012年，他还担任FDA科学和公共卫生副专员。在此之前，他从2003年到2009年担任FDA生物制品评估和研究中心的主任，从1998年到2000年担任FDA专员的高级顾问。在他的政府服务之前，古德曼博士是明尼苏达大学的医学教授和传染病主任。古德曼博士曾任职于许多国家和国际卫生保健组织的咨询委员会和委员会，包括疾病预防控制中心、国家卫生研究所、世界卫生组织、流行病防范创新联盟和国家科学院、工程学院和医学院。他持有Harvard College的生物学学士学位、Minnesota大学的公共卫生硕士学位和the Albert Einstein College of Medicine的医学博士学位，并在Pennsylvania大学和California大学in Los Angeles接受了医学、传染病和肿瘤学的住院医师和奖学金培训，在那里他也是首席住院医师。他被选为国家医学院院士。
Jesse Goodman has served as a director of the Company since March 2024. Dr. Goodman has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectio diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trtees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectio diseases at the University of Minnesota. Dr. Goodman has served on numero advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectio diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine. - Jesse Goodman， 2014年3月以来，他一直担任Georgetown大学医疗产品准入、安全和管理中心主任，以及医学教授和传染病主治医师。2016年至2025年，他担任跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会成员，并担任董事会科学委员会主席，直到2023年初。自2018年以来，他担任Intellia Therapeutics， Inc.（上市生物技术公司）的董事会成员，现担任其科学和技术委员会主席。在合并协议之前，他曾担任APT董事会成员。他还曾担任美国药典公约公司（United States Pharmacopeia Convention, Inc.）董事会主席（2015年至2020年）和成员（2015年至2025年）。从2009年到2014年2月，他担任FDA的首席科学家。从2009年到2012年，他还担任FDA科学和公共卫生副专员。在此之前，他从2003年到2009年担任FDA生物制品评估和研究中心的主任，从1998年到2000年担任FDA专员的高级顾问。在他的政府服务之前，古德曼博士是明尼苏达大学的医学教授和传染病主任。古德曼博士曾任职于许多国家和国际卫生保健组织的咨询委员会和委员会，包括疾病预防控制中心、国家卫生研究所、世界卫生组织、流行病防范创新联盟和国家科学院、工程学院和医学院。他持有Harvard College的生物学学士学位、Minnesota大学的公共卫生硕士学位和the Albert Einstein College of Medicine的医学博士学位，并在Pennsylvania大学和California大学in Los Angeles接受了医学、传染病和肿瘤学的住院医师和奖学金培训，在那里他也是首席住院医师。他被选为国家医学院院士。
- Jesse Goodman has served as a director of the Company since March 2024. Dr. Goodman has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectio diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trtees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectio diseases at the University of Minnesota. Dr. Goodman has served on numero advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectio diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine.
- Jonathan Solomon
-
Jonathan Solomon自2019年10月起担任公司首席执行官兼董事。所罗门先生于2017年5月至2019年10月担任Biomx首席执行官。Solomon从2007年7月到2015年12月担任Proclara Biosciences Inc.（前身为Neurophage Pharmaceuticals Inc.，一家生物技术公司，开创了治疗神经退行性疾病的方法）联合创始人、总裁和首席执行官。加入Proclara公司之前，他曾任职以色列国防军（the Israeli Defense Forces）的机密军事单位十年。Solomon先生持有B.SC.以优异成绩获得希伯来大学物理学和数学硕士学位。特拉维夫大学（Tel Aviv University）电气工程最优等成绩，以及工商管理硕士学位。the Harvard Business School的荣誉。
Jonathan Solomon,served as Board member of BiomX Israel from February 2016 and also as Chief Executive Officer from February 2017 to October 2019. From July 2007 to December 2015, Mr. Solomon was a co-founder, President, and Chief Executive Officer of ProClara Biosciences Inc. (formerly NeuroPhage Pharmaceuticals Inc.), a biotechnology company pioneering an approach to treating neurodegenerative diseases. Prior to joining ProClara, he served for ten years in a classified military unit of the Israeli Defense Forces. Mr. Solomon holds B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an MBA with honors from the Harvard Business School. - Jonathan Solomon自2019年10月起担任公司首席执行官兼董事。所罗门先生于2017年5月至2019年10月担任Biomx首席执行官。Solomon从2007年7月到2015年12月担任Proclara Biosciences Inc.（前身为Neurophage Pharmaceuticals Inc.，一家生物技术公司，开创了治疗神经退行性疾病的方法）联合创始人、总裁和首席执行官。加入Proclara公司之前，他曾任职以色列国防军（the Israeli Defense Forces）的机密军事单位十年。Solomon先生持有B.SC.以优异成绩获得希伯来大学物理学和数学硕士学位。特拉维夫大学（Tel Aviv University）电气工程最优等成绩，以及工商管理硕士学位。the Harvard Business School的荣誉。
- Jonathan Solomon,served as Board member of BiomX Israel from February 2016 and also as Chief Executive Officer from February 2017 to October 2019. From July 2007 to December 2015, Mr. Solomon was a co-founder, President, and Chief Executive Officer of ProClara Biosciences Inc. (formerly NeuroPhage Pharmaceuticals Inc.), a biotechnology company pioneering an approach to treating neurodegenerative diseases. Prior to joining ProClara, he served for ten years in a classified military unit of the Israeli Defense Forces. Mr. Solomon holds B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an MBA with honors from the Harvard Business School.
- Alan Moses
-
Alan Moses自2021年3月16日起担任我们的董事会成员。摩西博士是ABIM的董事会成员，并获得内分泌学和代谢方面的亚专科认证，并且是美国医师协会的会员。自2018年以来，摩西博士目前担任BioFabusa董事会成员。在此之前，Moses博士于2008年至2018年担任Novo NordiskA/SCPH:Novo-B的全球首席医疗官，他于2004年加入该公司。摩西博士于2002年至2006年担任哈佛医学院的医学教授，并与麻省理工学院合作，共同创立并共同指导了临床研究者培训计划，该计划专注于培训转化研究方面的医师-科学家。从1998年到2004年，Moses博士曾担任乔斯林糖尿病中心的高级副总裁兼首席医疗官。摩西博士拥有北卡罗来纳州杜克大学的学士学位和密苏里州华盛顿大学医学院的医学博士学位。
Alan Moses,has been a Board member of Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) since March 2021. Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S from 2013 until his retirement in 2018. Prior to that he served in various roles at Novo Nordisk A/S since 2004, beginning as Associate Vice President of Medical Affairs in the United States. Throughout his career, Dr. Moses has specialized in developing novel therapeutics and diagnostics for diabetes mellitus. He co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic, and has served as a member of the Board of Joslin Diabetes Center since December 2021. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. - Alan Moses自2021年3月16日起担任我们的董事会成员。摩西博士是ABIM的董事会成员，并获得内分泌学和代谢方面的亚专科认证，并且是美国医师协会的会员。自2018年以来，摩西博士目前担任BioFabusa董事会成员。在此之前，Moses博士于2008年至2018年担任Novo NordiskA/SCPH:Novo-B的全球首席医疗官，他于2004年加入该公司。摩西博士于2002年至2006年担任哈佛医学院的医学教授，并与麻省理工学院合作，共同创立并共同指导了临床研究者培训计划，该计划专注于培训转化研究方面的医师-科学家。从1998年到2004年，Moses博士曾担任乔斯林糖尿病中心的高级副总裁兼首席医疗官。摩西博士拥有北卡罗来纳州杜克大学的学士学位和密苏里州华盛顿大学医学院的医学博士学位。
- Alan Moses,has been a Board member of Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) since March 2021. Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S from 2013 until his retirement in 2018. Prior to that he served in various roles at Novo Nordisk A/S since 2004, beginning as Associate Vice President of Medical Affairs in the United States. Throughout his career, Dr. Moses has specialized in developing novel therapeutics and diagnostics for diabetes mellitus. He co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic, and has served as a member of the Board of Joslin Diabetes Center since December 2021. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School.
- Susan Blum
-
Susan Blum是Melinta Therapeutics，LLC（“Melinta”）的首席财务官，该公司专注于急性和危及生命的疾病的创新疗法的开发和商业化。Blum女士于2016年加入美林塔，担任公司财务总监，随后担任财务副总裁兼首席会计官，之后于2021年被任命为首席财务官职位。在加入Melinta之前，Blum女士于2013年至2016年在Textura Corporation担任公司控制人，支持公司首次公开发行股票并转型为上市组织。Blum女士还于2011年至2013年在Orbitz Worldwide, Inc.（NYSE：OWW）担任领导职务，并于2004年至2010年在Facet Biotech Corporation和PDL生物制药，Inc.（纳斯达克：PDLI）担任领导职务，负责外部报告和相关合规、技术会计和财务报告内部控制等职能。Blum女士在安永会计师事务所开始了她的公共会计职业生涯，在那里她花了近七年的时间与多元化的客户群合作，从大型公共国际业务到发展阶段的企业。Blum女士是一名注册会计师，目前担任BioNJ网络安全委员会成员，并拥有圣克拉拉大学商业商务学士学位。
Susan Blum has served as a director of the Company since April 2024. Ms. Blum is the Chief Financial Officer of Melinta Therapeutics, LLC (“Melinta”), a company foced on the development and commercialization of innovative therapies for acute and life threatening illnesses. Ms. Blum joined Melinta in 2016 as the company’s Controller and then served as Vice President of Finance & Chief Accounting Officer prior to being appointed to the Chief Financial Officer position in 2021. Prior to joining Melinta, Ms. Blum served as Corporate Controller at Textura Corporation from 2013 to 2016, supporting the company’s IPO and transformation into a publicly traded organization. Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010, where she was responsible for such functions as external reporting and related compliance, technical accounting and internal controls over financial reporting. Ms. Blum began her career in public accounting at Ernst & Young, where she spent nearly seven years working with a diverse client base ranging from large, public international engagements to development stage enterprises. Ms. Blum is a Certified Public Accountant, currently serves as a member of the BioNJ Cybersecurity Committee and holds a B.S. in Biness Commerce from Santa Clara University. - Susan Blum是Melinta Therapeutics，LLC（“Melinta”）的首席财务官，该公司专注于急性和危及生命的疾病的创新疗法的开发和商业化。Blum女士于2016年加入美林塔，担任公司财务总监，随后担任财务副总裁兼首席会计官，之后于2021年被任命为首席财务官职位。在加入Melinta之前，Blum女士于2013年至2016年在Textura Corporation担任公司控制人，支持公司首次公开发行股票并转型为上市组织。Blum女士还于2011年至2013年在Orbitz Worldwide, Inc.（NYSE：OWW）担任领导职务，并于2004年至2010年在Facet Biotech Corporation和PDL生物制药，Inc.（纳斯达克：PDLI）担任领导职务，负责外部报告和相关合规、技术会计和财务报告内部控制等职能。Blum女士在安永会计师事务所开始了她的公共会计职业生涯，在那里她花了近七年的时间与多元化的客户群合作，从大型公共国际业务到发展阶段的企业。Blum女士是一名注册会计师，目前担任BioNJ网络安全委员会成员，并拥有圣克拉拉大学商业商务学士学位。
- Susan Blum has served as a director of the Company since April 2024. Ms. Blum is the Chief Financial Officer of Melinta Therapeutics, LLC (“Melinta”), a company foced on the development and commercialization of innovative therapies for acute and life threatening illnesses. Ms. Blum joined Melinta in 2016 as the company’s Controller and then served as Vice President of Finance & Chief Accounting Officer prior to being appointed to the Chief Financial Officer position in 2021. Prior to joining Melinta, Ms. Blum served as Corporate Controller at Textura Corporation from 2013 to 2016, supporting the company’s IPO and transformation into a publicly traded organization. Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010, where she was responsible for such functions as external reporting and related compliance, technical accounting and internal controls over financial reporting. Ms. Blum began her career in public accounting at Ernst & Young, where she spent nearly seven years working with a diverse client base ranging from large, public international engagements to development stage enterprises. Ms. Blum is a Certified Public Accountant, currently serves as a member of the BioNJ Cybersecurity Committee and holds a B.S. in Biness Commerce from Santa Clara University.
- Jesse Goodman
-
Jesse Goodman，自2014年3月起担任乔治城大学医疗产品准入、安全和管理中心主任，以及传染病医学教授和主治医师。2016年至2025年，他在跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会任职，并担任该董事会科学委员会主席至2023年初。自2018年以来，他一直在上市的生物技术公司Intellia Therapeutics, Inc.的董事会任职，现在担任其科学和技术委员会主席。在合并协议之前，古德曼博士曾担任APT的董事会成员。他还曾担任美国药典公约公司总裁（2015年至2020年）和董事会成员（2015年至2025年）。2009年至2014年2月，古德曼博士担任FDA首席科学家。古德曼博士还曾在2009年至2012年期间担任FDA科学和公共卫生副专员。在此之前，古德曼博士曾于2003年至2009年担任FDA生物制品评估和研究中心主任，并于1998年至2000年担任FDA专员的高级顾问。在担任政府职务之前，古德曼博士是明尼苏达大学的医学教授和传染病学主任。古德曼博士曾在多个国家和国际医疗保健组织的咨询委员会和委员会任职，包括疾病预防控制中心、美国国家卫生研究院、世界卫生组织、疫情防备创新联盟以及美国国家科学院、工程院和医学院。古德曼博士在哈佛大学获得生物学学士学位，在明尼苏达大学获得公共卫生硕士学位，在阿尔伯特·爱因斯坦医学院获得医学博士学位，并在宾夕法尼亚大学医院和洛杉矶的加州大学进行了医学、传染病和肿瘤学方面的住院医师和研究金培训，他也是那里的首席医疗住院医师。他已入选美国国家医学研究院。
Jesse Goodman,has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectious diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trustees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectious diseases at the University of Minnesota. Dr. Goodman has served on numerous advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectious diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine. - Jesse Goodman，自2014年3月起担任乔治城大学医疗产品准入、安全和管理中心主任，以及传染病医学教授和主治医师。2016年至2025年，他在跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会任职，并担任该董事会科学委员会主席至2023年初。自2018年以来，他一直在上市的生物技术公司Intellia Therapeutics, Inc.的董事会任职，现在担任其科学和技术委员会主席。在合并协议之前，古德曼博士曾担任APT的董事会成员。他还曾担任美国药典公约公司总裁（2015年至2020年）和董事会成员（2015年至2025年）。2009年至2014年2月，古德曼博士担任FDA首席科学家。古德曼博士还曾在2009年至2012年期间担任FDA科学和公共卫生副专员。在此之前，古德曼博士曾于2003年至2009年担任FDA生物制品评估和研究中心主任，并于1998年至2000年担任FDA专员的高级顾问。在担任政府职务之前，古德曼博士是明尼苏达大学的医学教授和传染病学主任。古德曼博士曾在多个国家和国际医疗保健组织的咨询委员会和委员会任职，包括疾病预防控制中心、美国国家卫生研究院、世界卫生组织、疫情防备创新联盟以及美国国家科学院、工程院和医学院。古德曼博士在哈佛大学获得生物学学士学位，在明尼苏达大学获得公共卫生硕士学位，在阿尔伯特·爱因斯坦医学院获得医学博士学位，并在宾夕法尼亚大学医院和洛杉矶的加州大学进行了医学、传染病和肿瘤学方面的住院医师和研究金培训，他也是那里的首席医疗住院医师。他已入选美国国家医学研究院。
- Jesse Goodman,has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectious diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trustees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectious diseases at the University of Minnesota. Dr. Goodman has served on numerous advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectious diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine.
- Gregory Merril
-
Gregory Merril，于2016年10月创立Adaptive Phage Therapeutics（“APT”），担任首席执行官至2023年10月，并在其董事会任职至2024年3月。目前，他将自己的专业知识借给了多家初创公司，担任的职务从顾问到执行董事不等。Merril先生曾于2015年8月至2017年12月担任Yost Labs的首席执行官，该公司是惯性运动传感器Biomx Inc.在身体康复和无人机导航等领域的开发商。在2011年至2015年8月期间，他创立并领导了Brain Sentry，这是一家致力于开发可穿戴传感器的公司，用于检测在足球、曲棍球和曲棍球等运动中可能造成创伤性脑损伤的头部撞击。2009年10月至2011年2月，他担任Decision Technologies的首席运营官，该公司支持美国海军和导弹防御局的技术收购和部署。早些时候，作为Interaction Laboratories的创始首席执行官和主席，从2002年3月到2009年10月，Merril致力于在视频游戏和军事模拟中增强身体活动的专利和产品。此前，他是HT Medical Systems的创始首席执行官，该公司是一家专注于手术训练模拟器的公司，该公司于2000年7月与浸入科技公司（纳斯达克股票代码：IMMR）合并。Merril先生被认为是拥有22项已授权专利的发明家，并拥有麦克丹尼尔学院的心理生物学学士学位。
Gregory Merril,founded Adaptive Phage Therapeutics ("APT") in October 2016, and served as its Chief Executive Officer until October 2023 and served on its board of directors until March 2024. Currently, he lends his expertise to various startups, serving in capacities ranging from advisor to executive director. Mr. Merril served as Chief Executive Officer of Yost Labs, a developer of inertial motion sensors Biomx Inc. ed in fields such as physical rehabilitation and drone navigation, from August 2015 to December 2017. Between 2011 and August 2015, he founded and led Brain Sentry, a company dedicated to developing wearable sensors to detect head impacts risking traumatic brain injury in sports including football, hockey, and lacrosse. From October 2009 to February 2011, he served as chief operating officer of Decision Technologies, which supported the U.S. Navy and the Missile Defense Agency with technology acquisitions and deployments. Earlier, as the founding chief executive officer and chair of Interaction Laboratories from March 2002 to October 2009, Merril worked on patents and products that enhanced physical activity in video games and military simulations. Before this, he was the founding Chief Executive Officer of HT Medical Systems, a company focusing on surgical training simulators, which merged with Immersion Corp (NASDAQ: IMMR) in July 2000. Mr. Merril is credited as inventor with 22 issued patents and holds a B.A. in psychobiology from McDaniel College. - Gregory Merril，于2016年10月创立Adaptive Phage Therapeutics（“APT”），担任首席执行官至2023年10月，并在其董事会任职至2024年3月。目前，他将自己的专业知识借给了多家初创公司，担任的职务从顾问到执行董事不等。Merril先生曾于2015年8月至2017年12月担任Yost Labs的首席执行官，该公司是惯性运动传感器Biomx Inc.在身体康复和无人机导航等领域的开发商。在2011年至2015年8月期间，他创立并领导了Brain Sentry，这是一家致力于开发可穿戴传感器的公司，用于检测在足球、曲棍球和曲棍球等运动中可能造成创伤性脑损伤的头部撞击。2009年10月至2011年2月，他担任Decision Technologies的首席运营官，该公司支持美国海军和导弹防御局的技术收购和部署。早些时候，作为Interaction Laboratories的创始首席执行官和主席，从2002年3月到2009年10月，Merril致力于在视频游戏和军事模拟中增强身体活动的专利和产品。此前，他是HT Medical Systems的创始首席执行官，该公司是一家专注于手术训练模拟器的公司，该公司于2000年7月与浸入科技公司（纳斯达克股票代码：IMMR）合并。Merril先生被认为是拥有22项已授权专利的发明家，并拥有麦克丹尼尔学院的心理生物学学士学位。
- Gregory Merril,founded Adaptive Phage Therapeutics ("APT") in October 2016, and served as its Chief Executive Officer until October 2023 and served on its board of directors until March 2024. Currently, he lends his expertise to various startups, serving in capacities ranging from advisor to executive director. Mr. Merril served as Chief Executive Officer of Yost Labs, a developer of inertial motion sensors Biomx Inc. ed in fields such as physical rehabilitation and drone navigation, from August 2015 to December 2017. Between 2011 and August 2015, he founded and led Brain Sentry, a company dedicated to developing wearable sensors to detect head impacts risking traumatic brain injury in sports including football, hockey, and lacrosse. From October 2009 to February 2011, he served as chief operating officer of Decision Technologies, which supported the U.S. Navy and the Missile Defense Agency with technology acquisitions and deployments. Earlier, as the founding chief executive officer and chair of Interaction Laboratories from March 2002 to October 2009, Merril worked on patents and products that enhanced physical activity in video games and military simulations. Before this, he was the founding Chief Executive Officer of HT Medical Systems, a company focusing on surgical training simulators, which merged with Immersion Corp (NASDAQ: IMMR) in July 2000. Mr. Merril is credited as inventor with 22 issued patents and holds a B.A. in psychobiology from McDaniel College.
- Edward Williams
-
Edward 威廉姆斯，自2021年12月起担任BioAtla，Inc.（纳斯达克：BCAB）的董事会成员，该公司是一家上市的生物技术公司，专注于肿瘤学领域。2018年1月至2022年12月，他在上市的生物制药公司Catalyst Biosciences公司（纳斯达克：CBIO，现为GYRE）担任董事会成员。他目前还在Boone Memorial Health、Innovative Hematology，Inc.的非营利性医疗保健董事会担任董事。自2020年3月至2022年9月，威廉姆斯先生曾在Ascendis制药，Inc.（纳斯达克：ASND）担任首席执行官特别顾问和临时首席商务官等职务。在加入Ascendis之前，2006年至2017年1月，威廉姆斯先生在跨国制药和生物技术公司诺和诺德，Inc.（NYSE：NVO）担任美国生物制药高级副总裁兼总经理。在加入Novo之前，从2003年到2006年，威廉姆斯先生担任诺华制药公司呼吸和皮肤科业务部门的销售副总裁。威廉姆斯先生于1981年在Upjohn公司（Pharmacia & Upjohn）开始其职业生涯，后来担任销售副总裁至2001年7月，随后于2001年7月至2003年5月在与Searle合并后担任东北地区销售区域副总裁。威廉姆斯先生拥有西弗吉尼亚州亨廷顿的马歇尔大学和洛杉矶格兰布林的格兰布林州立大学的生物学和化学学士学位。
Edward Williams has served as a director of the Company since October 2023. Mr. Williams has served as a member of the board of directors of BioAtla, Inc. (Nasdaq: BCAB), a publicly traded biotechnology company focing on oncology, since December 2021. From January 2018 to December 2022, he served as a member of the board of directors of Catalyst Biosciences Inc. (Nasdaq: CBIO, now GYRE), a publicly traded biopharmaceutical company. He also currently serves as director on the non profit healthcare boards of Boone Memorial Health, and Innovative Hematology, Inc. From March 2020 to September 2022, Mr. Williams held the positions of Special Advisor to the Chief Executive Officer and Interim Chief Commercial Officer of Ascendis Pharma, Inc. (Nasdaq: ASND). Prior to Ascendis, from 2006 to January 2017, Mr. Williams served as Senior Vice President and General Manager of BioPharmaceuticals at Novo Nordisk, Inc. (NYSE: NVO), a multinational pharmaceutical and biotech company. Prior to Novo, from 2003 to 2006, Mr. Williams served as Vice President of Sales at the Respiratory and Dermatology Biness Unit at Novartis Pharmaceuticals Corporation. Mr. Williams started his career in 1981 at The Upjohn Company (Pharmacia & Upjohn), where he later served as Vice President of Sales until July 2001 and then as Regional Vice President of Sales of Northeast Region post merger with Searle, from July 2001 until May 2003. Mr. Williams holds a B.S. in Biology and Chemistry from the Marshall University, Huntington, WV, and the Grambling State University, Grambling, LA. - Edward 威廉姆斯，自2021年12月起担任BioAtla，Inc.（纳斯达克：BCAB）的董事会成员，该公司是一家上市的生物技术公司，专注于肿瘤学领域。2018年1月至2022年12月，他在上市的生物制药公司Catalyst Biosciences公司（纳斯达克：CBIO，现为GYRE）担任董事会成员。他目前还在Boone Memorial Health、Innovative Hematology，Inc.的非营利性医疗保健董事会担任董事。自2020年3月至2022年9月，威廉姆斯先生曾在Ascendis制药，Inc.（纳斯达克：ASND）担任首席执行官特别顾问和临时首席商务官等职务。在加入Ascendis之前，2006年至2017年1月，威廉姆斯先生在跨国制药和生物技术公司诺和诺德，Inc.（NYSE：NVO）担任美国生物制药高级副总裁兼总经理。在加入Novo之前，从2003年到2006年，威廉姆斯先生担任诺华制药公司呼吸和皮肤科业务部门的销售副总裁。威廉姆斯先生于1981年在Upjohn公司（Pharmacia & Upjohn）开始其职业生涯，后来担任销售副总裁至2001年7月，随后于2001年7月至2003年5月在与Searle合并后担任东北地区销售区域副总裁。威廉姆斯先生拥有西弗吉尼亚州亨廷顿的马歇尔大学和洛杉矶格兰布林的格兰布林州立大学的生物学和化学学士学位。
- Edward Williams has served as a director of the Company since October 2023. Mr. Williams has served as a member of the board of directors of BioAtla, Inc. (Nasdaq: BCAB), a publicly traded biotechnology company focing on oncology, since December 2021. From January 2018 to December 2022, he served as a member of the board of directors of Catalyst Biosciences Inc. (Nasdaq: CBIO, now GYRE), a publicly traded biopharmaceutical company. He also currently serves as director on the non profit healthcare boards of Boone Memorial Health, and Innovative Hematology, Inc. From March 2020 to September 2022, Mr. Williams held the positions of Special Advisor to the Chief Executive Officer and Interim Chief Commercial Officer of Ascendis Pharma, Inc. (Nasdaq: ASND). Prior to Ascendis, from 2006 to January 2017, Mr. Williams served as Senior Vice President and General Manager of BioPharmaceuticals at Novo Nordisk, Inc. (NYSE: NVO), a multinational pharmaceutical and biotech company. Prior to Novo, from 2003 to 2006, Mr. Williams served as Vice President of Sales at the Respiratory and Dermatology Biness Unit at Novartis Pharmaceuticals Corporation. Mr. Williams started his career in 1981 at The Upjohn Company (Pharmacia & Upjohn), where he later served as Vice President of Sales until July 2001 and then as Regional Vice President of Sales of Northeast Region post merger with Searle, from July 2001 until May 2003. Mr. Williams holds a B.S. in Biology and Chemistry from the Marshall University, Huntington, WV, and the Grambling State University, Grambling, LA.
- Jonathan Leff
-
Jonathan Leff从2014年11月起担任董事会成员。他目前担任Deerfield Management Company, L.P.（投资公司）的合伙人，曾从2013年1月起在该公司工作。此前，他曾于1996年7月-2012年12月在一家私募股权投资公司-Warburg Pincus工作，曾担任该公司总经理。他目前在Nivalis Therapeutics, Inc. 董事会任职；此前在Talon Therapeutics, Inc., Allos Therapeutics, Inc., Inspire Pharmaceuticals, Inc., InterMune, Inc.和Sophiris Bio Inc. 董事会任职。他目前还在数个私有企业董事会任职。他持有Harvard大学的学士学位和Stanford大学商学研究生院的工商管理硕士学位。
Jonathan Leff has served as a director of the Company since March 2024. Mr. Leff is a Partner at Deerfield Management Company, L.P. ("Deerfield") and Chairman of the Deerfield Institute. He joined Deerfield in 2013 and foces on venture capital and structured investments in biotechnology and pharmaceuticals. Prior thereto, Mr. Leff served as Managing Director at Warburg Pinc LLC from 2000 to 2012, where he led the firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff also previoly served as a member of the Executive Committee of the Board of the National Venture Capital Association ("NVCA"), and led NVCA's life sciences indtry efforts as Chair of NVCA's Medical Innovation and Competitiveness Coalition. He also served on the Emerging Companies Section Board of the Biotechnology Indtry Organization. Mr. Leff is involved in the governance of several not for profit organizations, including serving as a member of the board of directors of the Spinal Mcular Atrophy Foundation and sitting on the Columbia University Medical Center Board of Advisors. He currently serves on the board of directors of Larimar Therapeutics, Inc., a publicly traded biotechnology company. Mr. Leff also previoly served on the boards of several other publicly traded biotechnology and pharmaceutical companies, including ARS Pharmaceuticals, Inc., from 2022 to 2023, Proteon Therapeutics, Inc. from 2017 to 2019, AveXis, Inc. from 2014 to 2017 and Nivalis Therapeutics, Inc. from 2014 to 2016. He currently serves on the boards of several private biopharmaceutical companies and has previoly served on the boards of other privately held biopharmaceutical companies. Mr. Leff received his A.B. from Harvard University, MBA from the Stanford University Graduate School of Biness and M.S. in Biotechnology from Johns Hopkins University. - Jonathan Leff从2014年11月起担任董事会成员。他目前担任Deerfield Management Company, L.P.（投资公司）的合伙人，曾从2013年1月起在该公司工作。此前，他曾于1996年7月-2012年12月在一家私募股权投资公司-Warburg Pincus工作，曾担任该公司总经理。他目前在Nivalis Therapeutics, Inc. 董事会任职；此前在Talon Therapeutics, Inc., Allos Therapeutics, Inc., Inspire Pharmaceuticals, Inc., InterMune, Inc.和Sophiris Bio Inc. 董事会任职。他目前还在数个私有企业董事会任职。他持有Harvard大学的学士学位和Stanford大学商学研究生院的工商管理硕士学位。
- Jonathan Leff has served as a director of the Company since March 2024. Mr. Leff is a Partner at Deerfield Management Company, L.P. ("Deerfield") and Chairman of the Deerfield Institute. He joined Deerfield in 2013 and foces on venture capital and structured investments in biotechnology and pharmaceuticals. Prior thereto, Mr. Leff served as Managing Director at Warburg Pinc LLC from 2000 to 2012, where he led the firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff also previoly served as a member of the Executive Committee of the Board of the National Venture Capital Association ("NVCA"), and led NVCA's life sciences indtry efforts as Chair of NVCA's Medical Innovation and Competitiveness Coalition. He also served on the Emerging Companies Section Board of the Biotechnology Indtry Organization. Mr. Leff is involved in the governance of several not for profit organizations, including serving as a member of the board of directors of the Spinal Mcular Atrophy Foundation and sitting on the Columbia University Medical Center Board of Advisors. He currently serves on the board of directors of Larimar Therapeutics, Inc., a publicly traded biotechnology company. Mr. Leff also previoly served on the boards of several other publicly traded biotechnology and pharmaceutical companies, including ARS Pharmaceuticals, Inc., from 2022 to 2023, Proteon Therapeutics, Inc. from 2017 to 2019, AveXis, Inc. from 2014 to 2017 and Nivalis Therapeutics, Inc. from 2014 to 2016. He currently serves on the boards of several private biopharmaceutical companies and has previoly served on the boards of other privately held biopharmaceutical companies. Mr. Leff received his A.B. from Harvard University, MBA from the Stanford University Graduate School of Biness and M.S. in Biotechnology from Johns Hopkins University.
高管简历
中英对照 | 中文 | 英文- Jonathan Solomon
Jonathan Solomon自2019年10月起担任公司首席执行官兼董事。所罗门先生于2017年5月至2019年10月担任Biomx首席执行官。Solomon从2007年7月到2015年12月担任Proclara Biosciences Inc.（前身为Neurophage Pharmaceuticals Inc.，一家生物技术公司，开创了治疗神经退行性疾病的方法）联合创始人、总裁和首席执行官。加入Proclara公司之前，他曾任职以色列国防军（the Israeli Defense Forces）的机密军事单位十年。Solomon先生持有B.SC.以优异成绩获得希伯来大学物理学和数学硕士学位。特拉维夫大学（Tel Aviv University）电气工程最优等成绩，以及工商管理硕士学位。the Harvard Business School的荣誉。
Jonathan Solomon,served as Board member of BiomX Israel from February 2016 and also as Chief Executive Officer from February 2017 to October 2019. From July 2007 to December 2015, Mr. Solomon was a co-founder, President, and Chief Executive Officer of ProClara Biosciences Inc. (formerly NeuroPhage Pharmaceuticals Inc.), a biotechnology company pioneering an approach to treating neurodegenerative diseases. Prior to joining ProClara, he served for ten years in a classified military unit of the Israeli Defense Forces. Mr. Solomon holds B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an MBA with honors from the Harvard Business School.- Jonathan Solomon自2019年10月起担任公司首席执行官兼董事。所罗门先生于2017年5月至2019年10月担任Biomx首席执行官。Solomon从2007年7月到2015年12月担任Proclara Biosciences Inc.（前身为Neurophage Pharmaceuticals Inc.，一家生物技术公司，开创了治疗神经退行性疾病的方法）联合创始人、总裁和首席执行官。加入Proclara公司之前，他曾任职以色列国防军（the Israeli Defense Forces）的机密军事单位十年。Solomon先生持有B.SC.以优异成绩获得希伯来大学物理学和数学硕士学位。特拉维夫大学（Tel Aviv University）电气工程最优等成绩，以及工商管理硕士学位。the Harvard Business School的荣誉。
- Jonathan Solomon,served as Board member of BiomX Israel from February 2016 and also as Chief Executive Officer from February 2017 to October 2019. From July 2007 to December 2015, Mr. Solomon was a co-founder, President, and Chief Executive Officer of ProClara Biosciences Inc. (formerly NeuroPhage Pharmaceuticals Inc.), a biotechnology company pioneering an approach to treating neurodegenerative diseases. Prior to joining ProClara, he served for ten years in a classified military unit of the Israeli Defense Forces. Mr. Solomon holds B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an MBA with honors from the Harvard Business School.
- Merav Bassan
Merav Bassan自2019年10月起担任公司首席开发官。Bassan博士于2019年10月加入Biomx担任首席开发官。在此之前，她自2005年起在Teva Pharmaceutical Industries Limited担任多个开发职位，包括Vice President，2017年至2019年担任转化科学、专业临床开发研发主管，Vice President、疼痛与全球内科、项目领导、创新产品开发，2015年至2017年全球IR&；D，2009年至2015年全球IR&；D创新产品开发项目冠军，高级总监。Dr.Bassan持有B.SC.在生物学中，硕士学位。在特拉维夫大学（Tel Aviv University）获得人类遗传学博士学位和神经生物学博士学位，她在哈佛大学（Harvard University）的哈佛医学院（Harvard Medical School）完成神经科学博士后奖学金。
Merav Bassan,served in various development roles at Teva Pharmaceutical Industries Limited between 2005 and 2019, including Vice President, Head of Translational Sciences, Specialty Clinical Development R&D from 2017 to 2019, Vice President, Pain and Global Internal Medicine, Project Leadership, Innovative Product Development, Global IR&D from 2015 to 2017, and Project Champion, Senior Director, Innovative Product Development, Global IR&D from 2009 to 2015. Dr. Bassan holds a B.Sc. in Biology, a M.Sc. in Human Genetics and a Ph.D. in Neurobiology from Tel Aviv University, and she completed a Post-Doctoral Fellowship in Neuroscience at Harvard Medical School at Harvard University.- Merav Bassan自2019年10月起担任公司首席开发官。Bassan博士于2019年10月加入Biomx担任首席开发官。在此之前，她自2005年起在Teva Pharmaceutical Industries Limited担任多个开发职位，包括Vice President，2017年至2019年担任转化科学、专业临床开发研发主管，Vice President、疼痛与全球内科、项目领导、创新产品开发，2015年至2017年全球IR&；D，2009年至2015年全球IR&；D创新产品开发项目冠军，高级总监。Dr.Bassan持有B.SC.在生物学中，硕士学位。在特拉维夫大学（Tel Aviv University）获得人类遗传学博士学位和神经生物学博士学位，她在哈佛大学（Harvard University）的哈佛医学院（Harvard Medical School）完成神经科学博士后奖学金。
- Merav Bassan,served in various development roles at Teva Pharmaceutical Industries Limited between 2005 and 2019, including Vice President, Head of Translational Sciences, Specialty Clinical Development R&D from 2017 to 2019, Vice President, Pain and Global Internal Medicine, Project Leadership, Innovative Product Development, Global IR&D from 2015 to 2017, and Project Champion, Senior Director, Innovative Product Development, Global IR&D from 2009 to 2015. Dr. Bassan holds a B.Sc. in Biology, a M.Sc. in Human Genetics and a Ph.D. in Neurobiology from Tel Aviv University, and she completed a Post-Doctoral Fellowship in Neuroscience at Harvard Medical School at Harvard University.
- Marina Wolfson
Marina Wolfson自2019年12月起担任公司财务和运营Vice President。Wolfson女士的经验包括在大型制药和高科技公司以及风险投资基金工作。在加入该公司之前，Wolfson女士曾担任BioView Ltd.的财务Vice President。从2010年到2019年担任TASE，从2007年到2010年担任安永会计师事务所（Ernst&Young）的高级审计师，这是一家国际审计和业务咨询公司。Wolfson女士是以色列的注册会计师，并持有Ben-Gurion University的经济学和会计学学士学位（优等生）和工商管理硕士学位（优等生，主修金融）。
Marina Wolfson,served in several finance and operations roles in the Company from December 2019 to March 2022. Ms. Wolfson's experience includes working with large pharmaceutical and hi-tech companies, as well as venture capital funds. Prior to joining the Company, Ms. Wolfson worked as Vice President of Finance at BioView Ltd. (TASE:BIOV) from 2010 to 2019 and a senior auditor at Ernst & Young, from 2007 to 2010. Ms. Wolfson is a certified public accountant in Israel and holds a B.A in Economics and Accounting (with honors) and an MBA (with honors, specializing in finance) from Ben-Gurion University.- Marina Wolfson自2019年12月起担任公司财务和运营Vice President。Wolfson女士的经验包括在大型制药和高科技公司以及风险投资基金工作。在加入该公司之前，Wolfson女士曾担任BioView Ltd.的财务Vice President。从2010年到2019年担任TASE，从2007年到2010年担任安永会计师事务所（Ernst&Young）的高级审计师，这是一家国际审计和业务咨询公司。Wolfson女士是以色列的注册会计师，并持有Ben-Gurion University的经济学和会计学学士学位（优等生）和工商管理硕士学位（优等生，主修金融）。
- Marina Wolfson,served in several finance and operations roles in the Company from December 2019 to March 2022. Ms. Wolfson's experience includes working with large pharmaceutical and hi-tech companies, as well as venture capital funds. Prior to joining the Company, Ms. Wolfson worked as Vice President of Finance at BioView Ltd. (TASE:BIOV) from 2010 to 2019 and a senior auditor at Ernst & Young, from 2007 to 2010. Ms. Wolfson is a certified public accountant in Israel and holds a B.A in Economics and Accounting (with honors) and an MBA (with honors, specializing in finance) from Ben-Gurion University.